JP2009517412A5 - - Google Patents

Download PDF

Info

Publication number
JP2009517412A5
JP2009517412A5 JP2008542573A JP2008542573A JP2009517412A5 JP 2009517412 A5 JP2009517412 A5 JP 2009517412A5 JP 2008542573 A JP2008542573 A JP 2008542573A JP 2008542573 A JP2008542573 A JP 2008542573A JP 2009517412 A5 JP2009517412 A5 JP 2009517412A5
Authority
JP
Japan
Prior art keywords
group
carbon atoms
alkyl group
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008542573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009517412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2006/001963 external-priority patent/WO2007062526A1/en
Publication of JP2009517412A publication Critical patent/JP2009517412A/ja
Publication of JP2009517412A5 publication Critical patent/JP2009517412A5/ja
Pending legal-status Critical Current

Links

JP2008542573A 2005-11-30 2006-11-30 アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法 Pending JP2009517412A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74064205P 2005-11-30 2005-11-30
PCT/CA2006/001963 WO2007062526A1 (en) 2005-11-30 2006-11-30 Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation

Publications (2)

Publication Number Publication Date
JP2009517412A JP2009517412A (ja) 2009-04-30
JP2009517412A5 true JP2009517412A5 (enExample) 2009-12-17

Family

ID=38091843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008542573A Pending JP2009517412A (ja) 2005-11-30 2006-11-30 アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法

Country Status (8)

Country Link
US (2) US8227450B2 (enExample)
EP (1) EP1971615B1 (enExample)
JP (1) JP2009517412A (enExample)
CN (1) CN101405293B (enExample)
AU (1) AU2006319716B2 (enExample)
CA (1) CA2632095A1 (enExample)
ES (1) ES2452718T3 (enExample)
WO (1) WO2007062526A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
ES2452718T3 (es) 2005-11-30 2014-04-02 Taimed Biologics, Inc. Profármacos a base de lisina de inhibidores de la aspartil proteasa y procesos para su preparación
WO2008023273A2 (en) * 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics
AU2007337830A1 (en) 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Benzenesulfonamide derivatives as HIV protease inhibitors
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP2632895B1 (en) 2010-10-28 2018-10-03 Merck Canada Inc. Hiv protease inhibitors
EP2771332B1 (en) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2017209732A1 (en) * 2016-05-31 2017-12-07 Taimed Biologics, Inc. A long acting pharmaceutical composition of protease inhibitor
US10369129B2 (en) 2016-05-31 2019-08-06 Taimed Biologics, Inc. Long acting pharmaceutical composition of protease inhibitor

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013861A (en) 1985-02-28 1991-05-07 E. R. Squibb & Sons, Inc. Ester substituted aminoalkanoylureido amino and imino acid and ester compounds
SK32693A3 (en) 1990-10-11 1993-09-09 Boehringer Ingelheim Kg Cyclopeptides, a method of preparing them and their use as drugs
US5614522A (en) 1990-11-19 1997-03-25 G.D. Searle & Co. Retroviral protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
DK0656888T3 (da) 1992-08-25 1998-02-09 Searle & Co Sulfonylalkanoylaminohydroxyethylaminosulfonamider, anvendelige som retrovirale protease-inhibitorer
EP0656886B1 (en) 1992-08-25 1997-06-25 G.D. Searle & Co. N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors
US6022994A (en) 1992-08-25 2000-02-08 G. D. Searle &. Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
JPH06321950A (ja) 1993-05-14 1994-11-22 Takeda Chem Ind Ltd 水溶性ランカシジン誘導体
WO1995006998A1 (en) 1993-08-31 1995-03-09 Stanley Kugell Telephone billing method
DE69512220T2 (de) 1994-03-07 2000-03-16 Vertex Pharmaceuticals Inc. Sulfonamidderivate als aspartylprotease-inhibitoren
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0804428B1 (en) 1995-01-20 2007-12-26 G.D. Searle LLC. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5985870A (en) 1995-03-10 1999-11-16 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5776718A (en) 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2243121A1 (en) 1996-01-26 1997-07-31 Francesco Gerald Salituro Aspartyl protease inhibitors
US5859061A (en) 1997-01-17 1999-01-12 Pharmacia & Upjohn Company Bis-sulfonamides hydroxamic acids as MMP inhibitors
DE59802394D1 (de) 1997-05-09 2002-01-24 Hoechst Ag Substituierte Diaminocarbonsäuren
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AP2000001856A0 (en) * 1997-12-24 2000-09-30 Vertex Pharma Prodrugs of aspartyl protease inhibitors.
US5986102A (en) 1998-04-29 1999-11-16 Pharmacopeia, Inc. Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
ES2254156T3 (es) 1999-02-12 2006-06-16 Vertex Pharmaceuticals Incorporated Inhibidores de aspartil-proteasa.
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
CA2375511A1 (en) * 1999-06-16 2000-12-21 Temple University - Of The Commonwealth System Of Higher Education (z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors
US6455587B1 (en) 2000-03-15 2002-09-24 Pharmacor Inc. Amino acid derivatives as HIV aspartyl protease inhibitors
US6506786B2 (en) 2001-02-13 2003-01-14 Pharmacor Inc. HIV protease inhibitors based on amino acid derivatives
JP4283681B2 (ja) 2002-03-04 2009-06-24 アンブリリア バイオファーマ インコーポレーテッド Hivアスパルチルプロテアーゼ阻害剤としての尿素誘導体
CA2374362C (en) 2002-03-04 2008-01-22 Brent Richard Stranix Urea derivatives as hiv aspartyl protease inhibitors
KR20050085681A (ko) 2002-12-16 2005-08-29 베링거 인겔하임 인터내셔날 게엠베하 프로테아제 억제제와 같은 사이토크롬 p450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(nnrti)를함유하는 배합물의 용도
US6632816B1 (en) 2002-12-23 2003-10-14 Pharmacor Inc. Aromatic derivatives as HIV aspartyl protease inhibitors
CA2550187C (en) 2004-01-08 2012-08-07 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
ES2575871T3 (es) 2004-08-02 2016-07-01 Ambrilia Biopharma Inc. Composiciones farmacéuticas que comprende un compuesto a base de lisina y un agente antiviral o antirretroviral VIH
US20060287316A1 (en) 2005-04-27 2006-12-21 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
ES2452718T3 (es) 2005-11-30 2014-04-02 Taimed Biologics, Inc. Profármacos a base de lisina de inhibidores de la aspartil proteasa y procesos para su preparación
WO2008023273A2 (en) 2006-07-17 2008-02-28 Ambrilia Biopharma Inc. Method for improving pharmacokinetics
AU2007337830A1 (en) 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Benzenesulfonamide derivatives as HIV protease inhibitors

Similar Documents

Publication Publication Date Title
JP6401771B2 (ja) ヘモグロビンの修飾のための化合物及びその使用
JP2009517412A5 (enExample)
JP2017535555A5 (enExample)
JP2008523069A5 (enExample)
JP2008533191A5 (enExample)
JP2018513876A (ja) Dnaアルキル化剤
RU2014110400A (ru) Способ и промежуточные соединения для получения макролактамов
JP6799178B2 (ja) 4−メトキシピロール誘導体の中間体の製造方法
WO2015161781A1 (zh) 一种核苷类似物及其中间体的制备方法
KR20080008399A (ko) 비스(티오-히드라지드 아미드) 염의 합성 방법
JP2004511560A5 (enExample)
JP6781030B2 (ja) L−カルノシン誘導体またはその塩、及びl−カルノシンまたはその塩の製造方法
JP2018501268A (ja) チゾキサニドホスフェート及びアルカンスルホネート並びにその医薬用途
RU2019113149A (ru) Низкомолекулярные активаторы амфк
JP2007532625A5 (enExample)
CN110483417A (zh) 一种DACOs类NNRTIs氨基酸酯衍生物、其制备方法、药物组合物及应用
CN109734679B (zh) 一种异硫氰酸酯和磷氮硫系阻燃剂的联合制备方法
ATE419230T1 (de) Verfahren zur herstellung von 2,6-dihalo-para- trifluoromethylanilin
JP2007519685A5 (enExample)
JP7380555B2 (ja) 重合性化合物の製造方法
CN100491333C (zh) 高纯度烯胺类的制备方法
JP3303050B2 (ja) アゾニアアダマンタン化合物およびこのものからのアザアダマンタン化合物の製造方法並びに該アゾニアアダマンタン化合物の製造方法
JP2007534737A5 (enExample)
JP2006513137A5 (enExample)
RU2010105978A (ru) Производные фуранозы